Appointed
Peter Pitts
Director
BCLI ·
BRAINSTORM CELL THERAPEUTICS INC.
appointed Peter Pitts to serve as a director of the Company, effective as of the same day
Ready 8-Ks
33
Latest filing
May 28, 2026, 4:05 PM ET
Top materiality
0.85
Event mix
other_material ×11 · regulatory ×8 · earnings ×7
Sentiment
6 pos · 10 neg · 17 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for BCLI
Highest-materiality recent filing
BrainStorm delisted from Nasdaq; shares to trade on OTCQB from July 18
- Delisting due to non-compliance with Nasdaq minimum shareholder equity rule (Rule 5550(b)(1)).
- Nasdaq trading suspended at open on July 18, 2025; company received notice on July 16.
-
BrainStorm appoints former FDA official Peter Pitts to Board ahead of ALS trial
Appointed Peter Pitts, former FDA Associate Commissioner, to the Board effective May 25, 2026.
-
BrainStorm Q1 net loss $2.1M; cash below $0.2M; NurOwn Phase 3 preparations ongoing
Net loss $2.1M ($0.19 per share) vs $2.9M ($0.45) in Q1 2025; operating loss $2.0M.
-
BrainStorm reports FY2025 net loss $10.3M; secures $2M post-year-end for Phase 3b
Cash, equivalents, restricted cash $0.3M at Dec 31, 2025; raised $2M in Feb 2026 private placements.
-
BCLI issues three convertible notes to institutional investors, total ~$329K principal
Vanquish Funding: $94.3K note (12% OID), convertible at 65% of lowest trading price upon default, matures Oct 2026.
-
Brainstorm Cell Therapeutics issues $143,750 note to Labrys Fund II, reports Q3 2025 results
Entered securities purchase agreement with Labrys Fund II for a promissory note of $143,750, including $18,750 original issue discount, receiving net proceeds of $121,500.
-
BrainStorm Q2 net loss $2.9M; FDA clears Phase 3b NurOwn trial
Cash and equivalents total $1.03M as of June 30, 2025.
-
BrainStorm delisted from Nasdaq; shares to trade on OTCQB from July 18
Delisting due to non-compliance with Nasdaq minimum shareholder equity rule (Rule 5550(b)(1)).
-
Brainstorm Cell shareholders approve 2M share increase in equity plan pool
Shareholders approved increasing the shared pool under the 2014 plans by 2M shares, to 2,906,666 shares.
-
BrainStorm reports 90% of ALS patients in NurOwn EAP survived over 5 years
9 of 10 NurOwn EAP participants survived >5 years from symptom onset vs. ~10% typical survival in ALS.
-
BrainStorm receives FDA clearance to initiate Phase 3b trial of NurOwn for ALS
FDA cleared Phase 3b trial under Special Protocol Assessment (SPA); endpoints agreed for future BLA.
-
BrainStorm Q1 net loss $2.9M; advances NurOwn Phase 3b trial with IND amendment
Net loss of $2.9M ($0.45/share) improved vs $3.4M ($0.75/share) in Q1 2024.
-
Net loss of $11.6M ($2.31 per share) improved from $17.2M loss ($6.00 per share) in 2023.
-
Nasdaq Hearings Panel granted extension to June 30, 2025 to regain compliance with $35M minimum Market Value of Listed Securities.
-
BCLI fails to regain Nasdaq MVLS compliance; delisting stayed pending Feb 25 hearing
Company previously failed to meet Nasdaq's minimum market value of listed securities requirement by Jan 14, 2025.
-
Brainstorm Cell receives Nasdaq delisting notice for failure to meet MVLS minimum
Nasdaq notified BCLI on Jan 15, 2025 that it failed to regain compliance with the $35M MVLS requirement by the Jan 14 deadline.
-
BrainStorm Q3 net loss widens to $2.7M, cash at $0.35M; advancing NurOwn Phase 3b trial
Cash, equivalents, restricted cash only $0.35M as of Sept 30, 2024; net loss $2.7M ($0.51/shr) vs $1.2M ($0.45) YoY.
-
BrainStorm regains Nasdaq minimum bid price compliance; listing continues
Received Nasdaq notice of compliance on Oct 29, 2024; common stock continues on Nasdaq Capital Market.
-
Reverse stock split at 1:15 ratio effective 11:59 p.m. ET on September 30, 2024.
-
Brainstorm Cell shareholders OK 150M authorized share increase, reverse split, equity plan boost
Stockholders approved increasing authorized common shares from 100M to 250M.
-
BrainStorm Q2 net loss narrows to $2.5M; FDA alignment on NurOwn Phase 3b trial CMC
Net loss for Q2 2024 was $2.5M ($0.04/sh), compared to $5.3M ($0.13/sh) in Q2 2023.
-
Nasdaq warns Brainstorm Cell Therapeutics of MVLS deficiency; 180 days to comply
Received Nasdaq deficiency notice on July 18, 2024 for MVLS below $35M minimum.
-
BrainStorm Cell Therapeutics raises $4.0M in registered direct offering and warrants
Gross proceeds ~$4.0M from sale of 11.1M shares or pre-funded warrants at $0.36/share.
-
BrainStorm reaches alignment with FDA on CMC for NurOwn Phase 3b ALS trial
FDA alignment on Chemistry, Manufacturing, and Controls (CMC) for Phase 3b trial of NurOwn for ALS.
-
Brainstorm Cell Therapeutics appoints Hartoun Hartounian as EVP and COO, effective June 24, 2024
Hartoun Hartounian appointed EVP and COO, effective June 24, 2024.
-
Nasdaq grants Brainstorm Cell Therapeutics temporary exception until Oct 21 for bid price compliance
Company received delisting notice on May 1 for failing $1 minimum bid price; appealed on May 2.
Executive changes
Appointed
Hartoun Hartounian
Executive Vice President and Chief Operating Officer
BCLI ·
BRAINSTORM CELL THERAPEUTICS INC.
On June 20, 2024, Brainstorm Cell Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Hartoun Hartounian as its Executive Vice President and Chief Operating Officer, effective as of June 24, 2024 (the “Start Date”).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material